- Home
- ACRE vs ATYR Comparison
ACRE vs ATYR Comparison
Compare ACRE & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- ATYR
- Stock Information
- Founded
- ACRE 2011
- ATYR 2005
- Country
- ACRE United States
- ATYR United States
- Employees
- ACRE N/A
- ATYR N/A
- Industry
- ACRE Real Estate Investment Trusts
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRE Real Estate
- ATYR Health Care
- Exchange
- ACRE Nasdaq
- ATYR Nasdaq
- Market Cap
- ACRE 259.5M
- ATYR 290.6M
- IPO Year
- ACRE 2012
- ATYR 2015
- Fundamental
- Price
- ACRE $4.83
- ATYR $3.30
- Analyst Decision
- ACRE Hold
- ATYR Strong Buy
- Analyst Count
- ACRE 7
- ATYR 6
- Target Price
- ACRE $5.19
- ATYR $18.60
- AVG Volume (30 Days)
- ACRE 599.3K
- ATYR 1.1M
- Earning Date
- ACRE 05-07-2025
- ATYR 05-07-2025
- Dividend Yield
- ACRE 12.29%
- ATYR N/A
- EPS Growth
- ACRE N/A
- ATYR N/A
- EPS
- ACRE N/A
- ATYR N/A
- Revenue
- ACRE $67,129,000.00
- ATYR N/A
- Revenue This Year
- ACRE N/A
- ATYR $551.06
- Revenue Next Year
- ACRE $7.37
- ATYR $2,144.84
- P/E Ratio
- ACRE N/A
- ATYR N/A
- Revenue Growth
- ACRE 83.51
- ATYR N/A
- 52 Week Low
- ACRE $3.35
- ATYR $1.42
- 52 Week High
- ACRE $7.99
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- ACRE 70.34
- ATYR 52.29
- Support Level
- ACRE $4.03
- ATYR $3.06
- Resistance Level
- ACRE $4.00
- ATYR $3.45
- Average True Range (ATR)
- ACRE 0.18
- ATYR 0.24
- MACD
- ACRE 0.15
- ATYR 0.01
- Stochastic Oscillator
- ACRE 95.24
- ATYR 52.46
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.